Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment

Multiple Sclerosis Journal

Volumn 17, Issue 1, 2011, Pages 16-23

  Wipfler, P ^a   Oppermann, K ^a   Pilz, G ^a   Afazel, S ^a   Haschke Becher, E ^a   Harrer, A ^a   Huemer, M ^b   Kunz, A ^a   Golaszewski, S ^a   Staffen, W ^a   Ladurner, G ^a   Kraus, J ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Kardinal Schwarzenberg'sches Krankenhaus   (Austria)

Author keywords

adhesion molecules; multiple sclerosis; natalizumab; opportunistic infections; surrogate marker

Indexed keywords

ALPHA4 INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; INTERCELLULAR ADHESION MOLECULE 3; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NATALIZUMAB;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CELL MIGRATION; CELL SURFACE; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG INFUSION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE; TREATMENT RESPONSE;

EID: 78650970227     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510383075     Document Type: Article

References (26)

1. Lassmann H., Bruck W. and Lucchinetti C. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007 ; 17: 210-218.
2. Kermode AG, Thompson AJ, Tofts P., MacManus DG, Kendall BE, Kingsley DP, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990 ; 113: 1477-1489.
3. Kraus J. and Oschmann P. The impact of interferon-beta treatment on the blood-brain barrier. Drug Discov Today 2006 ; 11: 755-762.
4. Cannella B. and Raine CS The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995 ; 37: 424-435.
5. Springer TA Adhesion receptors of the immune system. Nature 1990 ; 346: 425-434.
6. Pilz G., Wipfler P., Ladurner G. and Kraus J. Modern multiple sclerosis treatment - what is approved, what is on the horizon. Drug Discov Today 2008 ; 13: 1013-1025.
7. Engelhardt B. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J Neurol Sci 2008 ; 274: 23-26.
8. Yednock TA, Cannon C., Fritz LC, Sanchez-Madrid F., Steinman L. and Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992 ; 356: 63-66.
9. Engelhardt B. and Kappos L. Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis 2008 ; 5: 16-22.
10. Archelos JJ, Previtali SC and Hartung HP The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci 1999 ; 22: 30-38.
11. Butcher EC Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991 ; 67: 1033-1036.
12. Fawcett J., Holness CL, Needham LA, Turley H., Gatter KC, Mason DY, et al. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature 1992 ; 360: 481-484.
13. Bo L., Peterson JW, Mork S., Hoffman PA, Gallatin WM, Ransohoff RM, et al. Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. J Neuropathol Exp Neurol 1996 ; 55: 1060-1072.
14. de Fougerolles AR, Stacker SA, Schwarting R. and Springer TA Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1. J Exp Med 1991 ; 174: 253-267.
15. Kraus J., Engelhardt B., Chatzimanolis N., Bauer R., Tofighi J., Kuehne BS, et al. Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity. J Neuroimmunol 2002 ; 122: 175-185.
16. Niino M., Bodner C., Simard ML, Alatab S., Gano D., Kim HJ, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006 ; 59: 748-754.
17. Polman CH, Reingold SC, Edan G., Filippi M., Hartung HP, Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ''McDonald Criteria''. Ann Neurol 2005 ; 58: 840-846.
18. Rieckmann P. [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006 )]. Nervenarzt 2006 ; 77: 1506-1518.
19. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452.
20. Kraus J., Engelhardt B., Kühne BS, Laske C., Stolz E., Traupe H., et al. Soluble and cell surface bound adhesion molecules in blood and cerebrospinal fluid as diagnostic markers and parameters for disease activity, disease severity and treatment efficacy in patients with multiple sclerosis. J Med Lab 2001 ; 25: 548-556.
21. Polman CH, O'Connor PW, Havrdova E., Hutchinson M., Kappos L., Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 899-910.
22. Dugger KJ, Zinn KR, Weaver C., Bullard DC and Barnum SR Effector and suppressor roles for LFA-1 during the development of experimental autoimmune encephalomyelitis. J Neuroimmunol 2009 ; 206: 22-27.
23. Kleine TO and Benes L. Immune surveillance of the human central nervous system (CNS): different migration pathways of immune cells through the blood-brain barrier and blood-cerebrospinal fluid barrier in healthy persons. Cytometry A 2006 ; 69: 147-151.
24. Kraus J., Bauer R., Chatzimanolis N., Engelhardt B., Tofighi J., Bregenzer T., et al. Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis. J Neurol 2004 ; 251: 464-472.
25. Bullard DC, Hu X., Schoeb TR, Collins RG, Beaudet AL and Barnum SR Intercellular adhesion molecule-1 expression is required on multiple cell types for the development of experimental autoimmune encephalomyelitis. J Immunol 2007 ; 178: 851-857.
26. Kraus J., Oschmann P., Engelhardt B., Stolz E., Kuehne BS, Laske C., et al. CD45RA+ ICAM-3+ lymphocytes in cerebrospinal fluid and blood as markers of disease activity in patients with multiple sclerosis. Acta Neurol Scand 2000 ; 102: 326-332.